

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

GLENN et al.

Appln. No. 09/257,188

Filed: February 25, 1999

For: USE OF PENETRATION ENHANCERS AND BARRIER
DISRUPTION AGENTS...



Atty. Ref.: 4057-32

Group: 1644

Examiner: G. Ewoldt

RECEIVED
JAN 04 2002
TECH CENTER 1600/2900

* * * * *
TERMINAL DISCLAIMER

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

Your petitioner, the U.S. Government, a corporation having an office and place of business at U.S. Army Medical Research and Material Command, HQ USAMRMC, Ft. Detrick, Maryland 21702-5012, represents that it is the assignee as recorded in an assignment at Reel 9832/Frame 0491, of all right, title and interest in and to this Application Serial No. 09/257,188, filed February 25, 1999, for Use Of Penetration Enhancers And Barrier Disruption Agents To Enhance The Transcutaneous Immune Response.

Your petitioner hereby disclaims the terminal part of any patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory term as presently shortened by any terminal disclaimer of any patent issuing from Application Serial No. 09/266,803 and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to such patent granted on the above-identified application shall be the same as the legal title to this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors or assigns.

Petitioner does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term as presently shortened by any terminal disclaimer of any patent issuing from Application Serial No. 09/266,803 in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration of its statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

The evidentiary documents accompanying this document or referred to above have been reviewed by the undersigned and it is certified that to the best of the assignee's knowledge and belief, title is in the assignee seeking to take action.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,

NIXON & VANDERHYDE P.C.

By: 

Gary R. Tanigawa
Reg. No. 43,180

Date: December 31, 2001